A new review highlights the pivotal role of LSD1 (lysine-specific demethylase 1) in regulating critical cellular processes ...

“It got my blood boiling,” Scolnick said. He began pursuing an emerging class of treatments called LSD1 inhibitors, hoping to ...

The two new compounds – LSD1 inhibitor EXS74539 and MALT1 protease inhibitor EXS73565 – both hit targets in cancer that have proved challenging for other drug developers, mainly as a result of ...

Image Caption: The structure of LSD1. By expanding our understanding of LSD1 and its modifications, this research provides a foundation for developing novel therapeutic strategies, offering hope ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

Oryzon has been invited to participate at the Van Lanschot Kempen Life Sciences Conference, which will take place in their offices located in Amsterdam (Netherlands) on April 1-3, where the company ...

Bomedemstat (IMG-7289) – an oral lysine-specific demethylase 1 (LSD1) inhibitor – is in multiple phase 2 trials for the treatment of indications including essential thrombocythemia (ET ...

Vafidemstat (ORY-2001) is an oral, CNS-optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same ...